Last reviewed · How we verify
Triamcinolone (Optional)
Triamcinolone is a synthetic corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors.
Triamcinolone is a synthetic corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors. Used for Inflammatory and allergic conditions (dermatitis, eczema, psoriasis), Rheumatoid arthritis and other joint disorders, Respiratory conditions (asthma, COPD).
At a glance
| Generic name | Triamcinolone (Optional) |
|---|---|
| Also known as | clobetasol |
| Sponsor | Eli Lilly and Company |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology, Dermatology, Rheumatology |
| Phase | FDA-approved |
Mechanism of action
Triamcinolone exerts its anti-inflammatory and immunosuppressive effects by binding to intracellular glucocorticoid receptors, which then translocate to the nucleus and modulate gene expression. This leads to decreased production of pro-inflammatory cytokines, reduced immune cell activation and migration, and suppression of inflammatory mediators. It is used topically, intramuscularly, intra-articularly, or systemically depending on the indication.
Approved indications
- Inflammatory and allergic conditions (dermatitis, eczema, psoriasis)
- Rheumatoid arthritis and other joint disorders
- Respiratory conditions (asthma, COPD)
- Adrenocortical insufficiency
- Systemic lupus erythematosus and other autoimmune diseases
Common side effects
- Immunosuppression / increased infection risk
- Hyperglycemia
- Hypertension
- Osteoporosis (with chronic use)
- Adrenal suppression
- Skin atrophy (topical use)
- Mood changes / psychiatric effects
Key clinical trials
- The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery) (PHASE4)
- A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triamcinolone (Optional) CI brief — competitive landscape report
- Triamcinolone (Optional) updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI